Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -31.16% is 82% above its 2-year average of -171.35%, near the high end of its 2-year range (-1108.55%–-15.35%).
24.63% below its 12-month average of -25.00%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -15.35%.
EBITDA MARGIN
-31.16%
EBITDA MARGIN AVG TTM
-25.00%
EBITDA MARGIN AVG 3Y
-171.35%
EBITDA MARGIN AVG 5Y
-171.35%
EBITDA MARGIN AVG 10Y
-171.35%
EBITDA MARGIN AVG 15Y
-280.08%
EBITDA MARGIN AVG 20Y
-512.96%
CURRENT VS TTM AVG
-24.63%
CURRENT VS 3Y AVG
+81.81%
CURRENT VS 5Y AVG
+81.81%
CURRENT VS 10Y AVG
+81.81%
CURRENT VS 15Y AVG
+88.87%
CURRENT VS 20Y AVG
+93.93%
Madrigal Pharmaceuticals, Inc.
Market Cap
$11.45B
EBITDA Margin
-31.16%
TTM Avg
-25.00%
3Y Avg
-171.35%
5Y Avg
-171.35%
Market Cap
$11.34B
EBITDA Margin
28.74%
TTM Avg
23.07%
3Y Avg
27.33%
5Y Avg
30.04%
Market Cap
$10.94B
EBITDA Margin
27.02%
TTM Avg
27.38%
3Y Avg
26.41%
5Y Avg
26.36%
Market Cap
$10.70B
EBITDA Margin
-29.58%
TTM Avg
-45.05%
3Y Avg
-68.49%
5Y Avg
-88.34%
Market Cap
$10.82B
EBITDA Margin
19.03%
TTM Avg
19.69%
3Y Avg
15.98%
5Y Avg
11.44%
Market Cap
$10.63B
EBITDA Margin
15.05%
TTM Avg
14.69%
3Y Avg
13.35%
5Y Avg
14.10%
Market Cap
$12.36B
EBITDA Margin
23.27%
TTM Avg
22.46%
3Y Avg
26.66%
5Y Avg
22.37%
Market Cap
$12.40B
EBITDA Margin
16.91%
TTM Avg
18.03%
3Y Avg
18.32%
5Y Avg
17.35%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. (MDGL) | $11.45B | -31.16% | -25.00% | -171.35% | -171.35% |
| Bio-Techne Corporation (TECH)vs › | $11.34B | 28.74% | 23.07% | 27.33% | 30.04% |
| DaVita Inc. (DVA)vs › | $11.64B | 19.98% | 20.97% | 19.78% | 20.10% |
| The Cooper Companies, Inc. (COO)vs › | $10.94B | 27.02% | 27.38% | 26.41% | 26.36% |
| Twist Bioscience Corporation (TWST)vs › | $10.70B | -29.58% | -45.05% | -68.49% | -88.34% |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $10.82B | 19.03% | 19.69% | 15.98% | 11.44% |
| Universal Health Services, Inc. (UHS)vs › | $10.63B | 15.05% | 14.69% | 13.35% | 14.10% |
| Encompass Health Corporation (EHC)vs › | $12.36B | 23.27% | 22.46% | 26.66% | 22.37% |
| ICON Public Limited Company (ICLR)vs › | $12.40B | 16.91% | 18.03% | 18.32% | 17.35% |
| 10x Genomics, Inc. (TXG)vs › | $10.42B | -10.43% | -17.56% | -24.27% | -20.72% |
Gross Margin
91.5%
EBITDA Margin
-31.2%
Operating Margin
-25.1%
Net Margin
-25.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -15.35% |
| 2026-03-31 | -29.66% |
| 2025-12-31 | -18.44% |
| 2025-09-30 | -39.55% |
| 2025-06-30 | -22.00% |
| 2025-03-31 | -57.51% |
| 2024-12-31 | -64.49% |
| 2024-09-30 | -186.58% |
| 2024-06-30 | -1108.55% |
| 2012-12-31 | -236.49% |
| 2012-03-31 | -9751.70% |
| 2011-12-31 | -290.62% |
| 2011-09-30 | -713.22% |
| 2011-06-30 | -858.57% |
| 2011-03-31 | -921.00% |
| 2010-12-31 | -195.74% |
| 2010-09-30 | -288.44% |
| 2010-06-30 | -254.82% |
| 2010-03-31 | -217.33% |
| 2009-12-31 | -138.14% |
| 2009-09-30 | 91.08% |
| 2009-06-30 | -167.78% |
| 2009-03-31 | -504.26% |
| 2008-12-31 | -3959.59% |
| 2008-09-30 | -2022.17% |
| 2008-06-30 | -1668.09% |
| 2008-03-31 | -1327.88% |
| 2007-12-31 | -2081.29% |
| 2004-03-31 | -5184.39% |
